Chao Huang is an Oncology physician. ClinicalTrials.gov lists 6 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3901 Rainbow Blvd
Kansas City, KS 661600001
Telephone
913-588-6029Registry record last updated 8 Jul 2007.
Clinical trials
- Comprehensive Oncogenomic Mapping and Exploration in Thoracic and Head & Neck Oncology
Sponsor: University of Kansas Medical Center
- A Clinical Trial of SIBP-A16 Injection in Healthy Adults
Sponsor: Shanghai Institute Of Biological Products
- Radiation Cystitis Treated With Pentosan Polysulfate Sodium Trial
Sponsor: National Taiwan University Hospital
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- Regeneron Healthcare Solutions, Inc.Program year20231 payment
- Novocure GmbHProgram year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
23.2%Opioid Agonist8.9%Oxycodone Hcl47%Tramadol Hcl38%Morphine Sulfate Er15%Part D<11 patientsGabapentinoids6.1%Gabapentin100%Part D≥17 patients+ 4 more classes in this area
Metabolism & gastrointestinal
21.4%Serotonin-3 Receptor Antagonist12.8%Ondansetron Hcl87%Ondansetron Odt13%Part D≥45 patientsPotassium supplement4.9%Potassium Chloride100%Part D≥22 patients+ 1 more class in this area
Cancer & immunology
16%Kinase inhibitor11.1%Tagrisso100%Part D≥13 patientsOther antineoplastic agents4.9%Lumakras100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”